Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $723.21 million. The enterprise value is $506.16 million.
| Market Cap | 723.21M |
| Enterprise Value | 506.16M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 20.01 million shares outstanding. The number of shares has increased by 12.28% in one year.
| Current Share Class | 20.01M |
| Shares Outstanding | 20.01M |
| Shares Change (YoY) | +12.28% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | 7.19% |
| Owned by Institutions (%) | 50.87% |
| Float | 11.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.63 |
| P/TBV Ratio | 3.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.64, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.64 |
| Quick Ratio | 10.50 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -40,409.00 |
Financial Efficiency
Return on equity (ROE) is -45.32% and return on invested capital (ROIC) is -29.73%.
| Return on Equity (ROE) | -45.32% |
| Return on Assets (ROA) | -27.97% |
| Return on Invested Capital (ROIC) | -29.73% |
| Return on Capital Employed (ROCE) | -54.40% |
| Weighted Average Cost of Capital (WACC) | 14.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$848,168 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.20% in the last 52 weeks. The beta is 1.95, so Neurogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | +71.20% |
| 50-Day Moving Average | 33.85 |
| 200-Day Moving Average | 25.47 |
| Relative Strength Index (RSI) | 54.16 |
| Average Volume (20 Days) | 172,359 |
Short Selling Information
The latest short interest is 2.93 million, so 14.63% of the outstanding shares have been sold short.
| Short Interest | 2.93M |
| Short Previous Month | 3.35M |
| Short % of Shares Out | 14.63% |
| Short % of Float | 25.82% |
| Short Ratio (days to cover) | 10.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | -88.38M |
| Operating Income | -121.23M |
| Pretax Income | -111.11M |
| Net Income | -111.11M |
| EBITDA | -117.99M |
| EBIT | -121.23M |
| Earnings Per Share (EPS) | -$5.04 |
Balance Sheet
The company has $225.39 million in cash and $8.35 million in debt, with a net cash position of $217.05 million or $10.85 per share.
| Cash & Cash Equivalents | 225.39M |
| Total Debt | 8.35M |
| Net Cash | 217.05M |
| Net Cash Per Share | $10.85 |
| Equity (Book Value) | 217.13M |
| Book Value Per Share | 13.72 |
| Working Capital | 207.41M |
Cash Flow
In the last 12 months, operating cash flow was -$86.82 million and capital expenditures -$890,000, giving a free cash flow of -$87.71 million.
| Operating Cash Flow | -86.82M |
| Capital Expenditures | -890,000 |
| Depreciation & Amortization | 3.24M |
| Net Borrowing | -43,000 |
| Free Cash Flow | -87.71M |
| FCF Per Share | -$4.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.28% |
| Shareholder Yield | -12.28% |
| Earnings Yield | -15.36% |
| FCF Yield | -12.13% |
Analyst Forecast
The average price target for Neurogene is $80.43, which is 122.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $80.43 |
| Price Target Difference | 122.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |